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1  | INTRODUC TION
Dent disease is an X-linked recessive kidney disease character-
ized by low-molecular-weight proteinuria (LMWP), hypercalci-
uria, aminoaciduria, nephrolithiasis and nephrocalcinosis.1 Two 
types are recognized: Dent disease type 1 is caused by CLCN5 
mutations (50%-60% incidence) and type 2 is caused by OCRL 
mutations (15% incidence).2,3 The CLCN5 gene encodes a ho-
modimeric 2Cl−/H+ exchanger, CLC5, which is mainly expressed 
on early endosomal membranes of cells of renal proximal tubules 
and the thick ascending limb of Henle's loop, suggesting a role in 
the receptor-mediated endocytic pathway responsible for protein 
absorption.4
More than 200 CLCN5 mutations are reported in Dent disease 
patients, and ~25% have been functionally analysed and classified 
into three classes according to their impact at the cellular and mo-
lecular levels.5 Class I mutations cause protein misfolding, being 
retained in the endoplasmic reticulum (ER) and degraded by the 
proteasome. Class II mutations result in delayed protein processing 
and reduced protein stability with decreased cell surface expression 
and function, but with normal distribution in early endosomes. Class 
III mutations have no influence on protein localization in early en-
dosomes or at the cell surface but do cause reduced or abolished 
Cl− conductance. A minority of mutations do not fit into any of these 
three classes, reflecting the limitation of the classification and the 
need for further functional analysis.
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Abstract
Dent disease type 1 is caused by mutations in the CLCN5 gene that encodes CLC5, a 
2Cl−/H+ exchanger. The CLC5 mutants that have been functionally analysed consti-
tute three major classes based on protein expression, cellular localization and channel 
function. We tested two small molecules, 4-phenylbutyrate (4PBA) and its analogue 
2-naphthoxyacetic acid (2-NOAA), for their effect on mutant CLC5 function and ex-
pression by whole-cell patch-clamp and Western blot, respectively. The expression 
and function of non-Class I CLC5 mutants that have reduced function could be re-
stored by either treatment. Cell viability was reduced in cells treated with 2-NOAA. 
4PBA is a FDA-approved drug for the treatment of urea cycle disorders and offers a 
potential therapy for Dent disease.
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No drugs targeting the molecular defects of Dent disease have 
been identified. Small molecules such as 4-phenylbutyrate (4PBA) 
are able to functionally restore a range of channelopathies associated 
with protein misfolding/instability (eg cystic fibrosis, bestrophinopa-
thies).6,7 We tested the effect of 4PBA and its analogue 2-naphthoxy-
acetic acid (2-NOAA) on the expression and function of mutant CLC5.
2  | MATERIAL S AND METHODS
Detailed materials and methods are provided in the online Supporting 
Information section.
3  | RESULTS
3.1 | Effect of 4PBA and 2-NOAA on CLC5 function
Wild type and 6 previously reported disease-causing mutant CLC5 
proteins were tested.8 Among them, p.S270R, p.G513E, p.R516W 
and p.I524K are Class I mutations that cause ER retention of the mu-
tant proteins and absence on the early endosome or plasma mem-
branes, resulting in abolished Cl− currents by patch-clamp analysis. 
The other two mutants, p.G57V and p.R280P, have reduced, but not 
abolished, function and plasma membrane expression compared to 
wild-type protein. The p.R280P mutant also expressed in early en-
dosomes that assign it to Class II mutation, while the p.G57V mutant 
was found in late endosomes, making it unclassified to any of the 
mutation classes described above.5,8
Transfected HEK293T cells expressing wild type or mutant CLC5 
were treated with 2.5 mmol/L 4PBA or 2-NOAA for 24 hours before 
patch-clamp analysis. Wild-type CLC5 gave robust Cl− currents with 
a strong outwardly rectifying current-voltage (I-V) relationship that 
was activated above +30 mV. All Class I mutants showed abolished 
Cl− conductance that was indistinguishable from untransfected 
HEK293T cells. p.G57V and p.R280P had a reduced Cl− conductance 
compared to wild-type protein. 4PBA and 2-NOAA had no effect 
on any of the Class I mutants but both significantly increased the 
Cl− conductance of wild type (44% increase with 4PBA and 52% in-
crease with 2-NOAA) and non-Class I mutants (p.G57V: +4PBA 48% 
to 85% of wild type, +2-NOAA 48% to 78%; p.R280P: +4PBA 36% 
to 66% of wild type, +2-NOAA 36% to 72%) (Figure 1A–G, K and 
L). These findings were then validated in opossum kidney (OK) cells 
derived from proximal tubule epithelium, the endogenous cell that 
CLC5 is normally expressed in (Figure 1H–J, M). These data show 
that the small molecules 4PBA and 2-NOAA can restore Cl− conduc-
tance to non-Class I CLC5 mutants that can exit the ER.
3.2 | Effect of 4PBA and 2-NOAA on 
CLC5 expression
In order to investigate whether the increased function is due to in-
creased CLC5 expression, transfected HEK293T cells were treated 
with 2.5 mmol/L 4PBA or 2-NOAA for 24 hours before harvesting 
for Western blotting. Anti-GFP antibody was used to detect YFP-
tagged CLC5 and anti-β-actin antibody was used as a loading con-
trol. The full-length, glycosylated CLC5-YFP protein (110 kDa) was 
F I G U R E  1   Effect of 4PBA and 2-NOAA on CLC5 function. A–G, I-V relationships of wild type and each mutant CLC5 with or without 
4PBA or 2-NOAA treatment in HEK293T cells. H-J, I-V relationships of wild-type and non-Class I mutant CLC5 with or without 4PBA or 
2-NOAA treatment in OK cells. K, Current densities at +200 mV of wild type and mutant CLC5 with 4PBA treatment in HEK293T cells. L, 
Current densities at +200 mV of wild type and mutant CLC5 with 2-NOAA treatment in HEK293T cells. M, Current densities at +200 mV of 
wild type and non-Class I mutant CLC5 with 4PBA or 2-NOAA treatment in OK cells. Data are presented as mean ± s.e.m. *P < .05, **P < .01 
and ***P < .001 indicate significant differences between groups. WT = wild type. n = number of cells recorded
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detected in lysates from cells expressing wild type or mutant CLC5. 
4PBA treatment significantly increased the expression of wild type, 
p.G57V, p.R280P and p.G513E CLC5 proteins. 2-NOAA did not in-
crease the expression of either the wild type or mutant proteins, 
which may be partially explained by the notable cell death during the 
24 hours treatment period (Figure 2A–C).
3.3 | Effect of 4PBA and 2-NOAA on HEK293T 
cell viability
Cell death was observed in cell cultures treated with 2-NOAA, and 
the reduced expression of some proteins seen by Western blotting 
led to the suspicion that 2-NOAA was cytotoxic to HEK293T cells. 
The MTT cell viability assay was used to determine the cytotoxicity 
of 2.5 mmol/L 4PBA and 2-NOAA on HEK293T cells. Results are 
shown as cell viability (%) relative to control (untreated) group. 4PBA 
had no significant effect on cell viability. 2-NOAA treatment caused 
the death of more than half the cells, with a cell viability of 32% com-
pared to the untreated cells (Figure 2D).
4  | DISCUSSION
CLC5 is a 2Cl−/H+ exchanger mainly expressed on the early endosome 
membrane and facilitates the endocytosis of low-molecular-weight 
proteins in proximal tubules, corresponding with the key clinical fea-
ture of Dent disease, LMWP. Similar to other protein misfolding dis-
eases, the majority of CLC5 mutants studied to date cause decreased 
expression of the mature protein, rapid degradation by the protea-
some, mislocalization and reduced or abolished Cl− conductance.5 
4PBA is an FDA-approved drug used for the treatment of urea cycle 
disorders, where it provides an alternative pathway to the urea cycle 
for the excretion of excess nitrogen. It can also act as a chemical chap-
erone that assists protein folding, and as a histone deacetylase inhibi-
tor that regulates gene transcription (eg up-regulates stress response 
F I G U R E  2   Effect of 4PBA and 
2-NOAA on CLC5 expression and 
HEK293T cell viability. A, Representative 
Western blots of wild type and non-Class 
I mutant CLC5 (p.G57V and p.R280P) 
with 4PBA or 2-NOAA treatment. B, 
Representative Western blots of Class 
I mutant CLC5 (p.S270R, p.G513E, 
p.R516W and p.I524K) with 4PBA or 
2-NOAA treatment. C, Quantification of 
Western blot data from 3 independent 
experiments is presented as mean ± s.e.m. 
*P < .05 and **P < .01 indicate significant 
differences between groups. The 
untreated controls are taken as 1. D, 
HEK293T cell viability with or without 
treatment (2.5 mmol/L 4PBA or 2-NOAA 
treatment for 24 hours) determined by 
MTT assay. Untreated group is taken as 
100% in the graph. Data were collected 
from 3 independent experiments and are 
presented as mean ± s.e.m. WT = wild 
type
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gene expression).9 2-NOAA, a 4PBA analogue, has been shown to be 
more potent in suppressing ER stress compared to 4PBA.10 The cell 
electrophysiology showed that only the function of the p.G57V and 
p.R280P mutants that exit the ER were rescued by the addition of 
4PBA or 2-NOAA. None of the Class I mutants that are retained in 
the ER were functionally rescued. These effects were seen in both 
HEK293T cells and the proximal tubule epithelium endogenous cell 
type. These data were supported by the Western blot experiment 
that showed the expression of p.G57V and p.R280P was increased 
by small molecule treatment. As the ER-retained Class I mutant pro-
teins may have more serious defects in protein folding compared to 
non-Class I CLC5 mutants that are released from the ER, the former 
would be expected to be more difficult, or impossible, to functional 
rescue by small molecules. A similar finding was noted in the ivacaftor 
treatment of mutant CFTR associated with cystic fibrosis where the 
amount of therapeutic effect correlated with the degree of disruption 
in CFTR protein processing and/or channel function.11
In conclusion, our data demonstrate that non-Class I CLC5 pro-
tein mutated in Dent disease type 1 can be functionally rescued by 
small molecule treatment. The absence of any functional rescue of 
Cl− conductance to Class I mutants suggests that different patho-
genic mechanisms result from different classes of mutation and that 
these are important considerations when contemplating small mole-
cule treatment. 2-NOAA treatment was associated with substantial 
toxicity, indicating that therapeutic safety can differ dramatically be-
tween compounds with minimal structural differences. Future work 
will investigate the effect of 4PBA on the physiological function of 
CLC5 such as endosomal acidification and endocytosis.
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